Loading clinical trials...
Loading clinical trials...
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Conditions
Interventions
Tiespectus
Aflibercept
Locations
20
United States
Retinal Consultants Medical Group (Site 024)
Modesto, California, United States
Retina Consultants of Southern California (Site 043)
Redlands, California, United States
Retinal Consultants Medical Group (Site 020)
Sacramento, California, United States
Retinal Consultants Medical Group (Site 022)
Sacramento, California, United States
Retina Group of Florida (Site 070)
Fort Lauderdale, Florida, United States
Fort Lauderdale Eye Institute (Site 042)
Plantation, Florida, United States
Start Date
March 27, 2026
Primary Completion Date
June 30, 2028
Completion Date
June 30, 2028
Last Updated
April 23, 2026
NCT05407636
NCT07308639
NCT07441642
NCT05913063
NCT07144137
NCT07392255
Lead Sponsor
EyeBiotech Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions